US FDA Commish Defends Approach To Apple Approvals
Executive Summary
After industry stakeholders raised concerns that Apple may have received preferential treatment when US FDA approved heart-rhythm apps on the Apple Watch Series 4, Commissioner Scott Gottlieb states in a blog post that the agency's approach was in accordance with its standard procedures and reflect the benefit of early interaction with FDA.
You may also be interested in...
FDA Explains Why It Approved Apple Watch's De Novo Despite Missing Primary Endpoint
De novo summary documents published by the US FDA sheds more light on the agency’s work approving two de novos for Apple Watches last year. At the time, the approvals sparked concern from industry stakeholders on whether the company received preferential treatment. Former FDA Commissioner Scott Gottlieb pushed back against the notion in a lengthy blog post late last year.
Drug/Software Combo Pathway Coming Soon To US FDA, Gottlieb Says
Under a new regulatory platform, drugs could soon be approved with accompanying software applications that could monitor adverse events or patient compliance without a separate pre-market device review.
Drug/Software Combo Platform Coming Soon To US FDA, Gottlieb Says
Under new platform, drugs could soon be approved with accompanying software applications that could monitor adverse events or patient compliance without a separate premarket device review.